Yes, obesity is recognized as a chronic disease by major medical organizations worldwide. The American Medical Association formally classified it as a disease in 2013, and the policy was reaffirmed in 2023. This classification reflects decades of evidence showing that obesity involves lasting changes in how the body regulates weight, appetite, and energy use, not simply a failure of willpower.
Why Medical Organizations Changed the Label
For most of the 20th century, obesity was treated as a risk factor for other diseases or as a lifestyle problem. That changed as research revealed the biological mechanisms driving it. The AMA’s 2013 resolution specifically recognized obesity as “a disease state with multiple pathophysiological aspects requiring a range of interventions to advance obesity treatment and prevention.” The World Health Organization had already been classifying obesity with its own diagnostic codes for years, and the CDC now provides specific billing codes (E66.811 through E66.813) that correspond to three classes of obesity based on BMI.
These codes matter in practical terms. When obesity has its own diagnosis, clinicians can treat it as a primary condition rather than just a side note on a chart. It also opens the door for insurance coverage of treatments specifically targeting weight loss, which historically were excluded from many plans.
The Biology Behind the Classification
The strongest argument for calling obesity a chronic disease is what happens inside the body. Fat tissue isn’t just storage. It functions as an active organ, releasing hormones that influence hunger, blood sugar regulation, and inflammation throughout the body.
One of the most important hormones involved is leptin, which normally signals the brain to reduce appetite when fat stores are sufficient. In people with obesity, the brain becomes resistant to leptin despite high circulating levels. This means the normal “stop eating” signal gets muted. Attempts to treat obesity by simply giving patients extra leptin have failed in clinical trials, producing no meaningful weight loss or metabolic improvement. At the same time, lower levels of another hormone produced by fat tissue reduce insulin sensitivity and the body’s ability to burn fat efficiently.
This hormonal disruption is why obesity behaves like other chronic diseases. The underlying biology doesn’t resolve on its own, and it actively works against treatment efforts.
Why Lost Weight Comes Back
Perhaps the most compelling evidence that obesity is a chronic condition is the body’s response to weight loss. Over 80% of people who lose significant weight eventually regain it. This isn’t a character flaw. It’s a measurable set of biological countermeasures.
When you lose weight, your body interprets the energy deficit as a threat. It responds by increasing hunger hormones, shifting food preferences toward high-calorie and high-sugar options, and reducing the rate at which you burn energy at rest. A 10% weight loss can trigger a 20 to 25% reduction in total energy expenditure, meaning your metabolism slows by 10 to 15% more than you’d expect from the change in body size alone. Leptin levels drop, thyroid activity decreases, and the nervous system dials back the energy your muscles burn just to maintain temperature.
These compensatory changes can persist for years after weight loss. When people stop actively restricting calories or reduce physical activity, the body’s regulatory system pushes weight back toward its previous level. This is what researchers call the “set point” mechanism, and it explains why short-term diets rarely produce lasting results. The biology of obesity requires ongoing management, much like type 2 diabetes or high blood pressure.
Genetics Play a Major Role
Twin studies consistently show that genetics account for a large share of BMI variation. A systematic review and meta-regression found that heritability estimates from twin studies ranged from 47% to 90%, with a median of 75%. Family studies produced lower but still substantial estimates, with a median of 46%. In other words, roughly half to three-quarters of the variation in body weight across a population traces back to inherited factors rather than individual choices.
This doesn’t mean genes guarantee obesity. It means some people’s biology makes weight gain far easier and weight loss far harder in the same food environment. The interaction between genetic predisposition and modern food availability is what drives population-level trends.
Conditions That Travel With Obesity
Obesity rarely exists in isolation. A large U.S. study examining chronic conditions among adults with obesity found striking overlap: 42.2% had hypertension, 37.4% had high cholesterol, 30.2% had arthritis, and 26.4% had depression. Diabetes affected 16.7%, asthma 13.4%, and heart disease or stroke 9.2%. Kidney disease and cancer were less common but still elevated at 3.9% and 6.9% respectively.
Globally, 1 in 8 deaths attributed to non-communicable diseases are driven by overweight or obesity, primarily through diabetes, stroke, coronary heart disease, and cancer. More than 1 billion people currently live with obesity, and projections from the World Obesity Federation suggest that by 2035, over 1.5 billion people will be affected, representing 54% of all adults worldwide when combined with those who are overweight. The burden falls disproportionately on people in socioeconomically deprived regions, older adults, minorities, and people with disabilities.
How the Label Affects Insurance Coverage
Classifying obesity as a disease has direct financial implications. Historically, Medicare Part D explicitly excluded medications used “for weight loss.” Coverage was only available when those same drugs were prescribed for a different approved condition, like type 2 diabetes or cardiovascular disease. In November 2024, the Centers for Medicare and Medicaid Services proposed reinterpreting that exclusion to allow coverage of anti-obesity medications when prescribed specifically to treat obesity.
If finalized, the change would expand coverage to an estimated 3.4 million additional Medicare enrollees. The proposal would also apply to Medicaid, potentially giving around 4 million more adults access to prescribed medications. The projected cost is substantial: $24.8 billion for Medicare and $14.8 billion for Medicaid over ten years. These numbers reflect both the scale of the condition and the shift in how the healthcare system treats it.
The Debate Isn’t Settled for Everyone
Not all researchers are comfortable with the disease label. One concern is that calling obesity a disease could worsen the stigma people already face. There’s also evidence that the label may backfire psychologically. One study found that framing obesity as a disease reduced people’s concern about their weight and predicted higher-calorie food choices among those with higher BMIs, possibly because the label made weight feel less within personal control.
Critics have called for more extensive investigation into how the disease classification affects stigma, self-efficacy, and psychosocial wellbeing before fully committing to it. The concern isn’t that obesity lacks biological underpinnings. It’s that labels carry social weight, and a disease framework could either empower patients to seek treatment or leave them feeling that change is out of their hands. Both effects appear to be real, and they can coexist in the same person.
What is no longer debatable is the biology. Obesity involves measurable hormonal disruption, genetic predisposition, and metabolic adaptations that resist treatment and persist over time. Whether you call that a disease, a chronic condition, or something else, the clinical reality is the same: it requires sustained, long-term management rather than a one-time fix.